This study is being conducted to investigate whether psilocybin, a naturally occurring compound, can offer a new and effective treatment for Obsessive Compulsive Disorder (OCD). OCD is often challenging to treat, and many individuals do not experience sufficient relief from traditional therapies like medication or Exposure and Response Prevention (ERP). By studying psilocybin’s effects on OCD symptoms, as well as related conditions like depression and anxiety, researchers at Johns Hopkins aim to evaluate its safety, feasibility, and potential to improve overall quality of life for those with OCD. This research could pave the way for innovative treatment options for individuals struggling with this condition.

If you participate in this study, your journey will involve several key steps over approximately 8–10 months:

1. Screening and Preparation: After an initial screening to confirm your eligibility, you’ll taper off any daily psychiatric medications over up to 8 weeks. You’ll then attend preparation sessions with study staff to get ready for two psilocybin sessions.

2. Psilocybin Sessions: You’ll take part in two full-day psilocybin sessions at the Johns Hopkins Behavioral Pharmacology Research Unit (BPRU), spaced about two weeks apart. These sessions will be conducted in a supportive, supervised setting to ensure your safety and comfort.

3. Follow-Up and Monitoring: Following each session, you’ll meet with the research staff and guides to reflect on your experience and monitor your progress. You’ll also participate in follow-up assessments at 1, 2, 3, and 6 months after your second session, some of which may be conducted virtually.